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Delayed graft function (DGF), especially long-lasting DGF,
complicates kidney transplant outcome. Neutrophil
gelatinase-associated lipocalin (NGAL) is an acute kidney
injury marker; therefore, we tested whether urine NGAL
could predict DGF, prolonged DGF (lasting over 14 days), or
the quality of kidney function in transplant recipients without
DGF (non-DGF). We collected urine samples from 176
recipients transplanted with deceased donor kidneys before
and various days after transplantation. A total of 70
transplantations had DGF, of which 26 were prolonged.
Patients who developed DGF had a significantly slower
decrease in urinary NGAL compared with those without DGF,
such that day 1 NGAL predicted DGF (area under the curve
(AUC) 0.75) and predicted DGF in 15 of 112 cases with day 1
urine output over 1 l (AUC 0.70) and in 19 of 86 cases with a
day 1 decrease in creatinine over 50lmol/l (AUC 0.74). The
urinary NGAL level on day 1 predicted prolonged DGF (AUC
0.75), which had significantly worse 1-year graft survival
(73%), compared with shorter DGF (100%). In non-DGF, high
day 3 NGAL (greater than the mean) was associated with
significantly worse kidney function at 3 weeks compared
with low NGAL, but not at 3 months and 1 year. NGAL did not
correlate with long-term function in DGF. Hence, day 1
urinary NGAL predicted DGF even when it was not clinically
expected early on, and importantly, it predicted prolonged
DGF that led to worse graft survival.
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Delayed graft function (DGF) is an increasing problem after
deceased donor kidney transplantation, as more kidneys from
expanded criteria donors are accepted for transplantation.
DGF is associated with acute rejection, increases the need for
dialysis and posttransplantation biopsies, extends the post-
transplantation hospital stay, and causes considerable eco-
nomic burden.1–8 In addition, the length of DGF is associated
with worse 1-year outcome.4,9 Ischemia-reperfusion injury
occurs in all deceased donor transplantations, and has a
major role in the pathogenesis of DGF. DGF can thus be
regarded as one type of acute kidney injury.10 Despite
extensive studying on the mechanisms of ischemia-reperfu-
sion injury in the experimental models, very little has been
achieved in the prevention and treatment of DGF from the
clinical point of view. Therefore, finding new ways to
diagnose DGF very soon after, or even before transplantation,
would further the possibility of developing therapeutic
methods to prevent DGF in a clinical setting.
Neutrophil gelatinase-associated lipocalin (NGAL) has
emerged as a new, noninvasive diagnostic tool for acute
kidney injury.11–16 NGAL associates with DGF; the associa-
tion has been shown in kidney transplant biopsies taken 1 h
after reperfusion, and in urine and serum samples taken on
the day of, and very soon after, transplantation.17–21
The aim of our study was to examine (1) how serial urine
NGAL (uNGAL) concentrations change over time after
kidney transplantation; (2) whether uNGAL predicts the
onset of kidney graft function; (3) whether uNGAL predicts
prolonged DGF; and (4) whether uNGAL correlates with the
level of kidney function in transplantations with early graft
function (EGF).
RESULTS
The study included 176 renal transplant recipients. Recipient
pretransplantation, posttransplantation, and donor charac-
teristics are presented in Tables 1, 2, and 3. All recipients were
Caucasian, except for one. The DGF grafts started to function
from mean 12.0 days (s.d. 7.0) after transplantation. The
donors in the DGF group were older, expanded criteria
donors22 were more common, cold ischemia time was longer,
pretransplantation hemodialysis was more common, and
time on dialysis before transplantation was longer in the DGF
group compared with the EGF group. Overall 1-year patient
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survival was 98.9%, and graft survival was 95.5%. The 1-year
graft survival and long-term (3 month and 1 year) graft
function were inferior in the DGF group, compared with the
EGF group.
A pretransplantation urine sample was obtained from 70
patients, as 106 patients were anuric or oliguric before
transplantation. The pretransplantation uNGAL did not
correlate with residual diuresis from the native kidneys of
the recipients (R¼ 0.089, p¼NS). The mean uNGAL levels
decreased after transplantation in both DGF and EGF groups
(Figure 1). The mean uNGAL concentrations were signifi-
cantly lower in the EGF group compared with the DGF group
at all measured time points after transplantation. Recipient’s
posttransplantation uNGAL was not affected by donor age,
gender, or by induction immunosuppression given to the
recipient (data not shown).
We included in the multivariate analysis (multilogistic
regression method, forward, conditional) factors significantly
differing between the DGF and EGF groups in the univariate
analyses and also the clinically relevant factors in this respect,
such as recipient age, donor plasma creatinine, and donor-
estimated glomerular filtration rate (eGFR) (Table 4). Day 1
urine output, day 1 uNGAL, and the mode of dialysis
emerged as significant, independent predictors of DGF.
Receiver operating characteristic (ROC) analyses were
performed to assess the potential of uNGAL in predicting
DGF. The area under the curve (AUC) for day 1 uNGAL was
0.750 (confidence interval (CI) 0.663–0.837; Po0.0001). At
the optimal cutoff level of 560 ng/ml, the sensitivity was 68%
and the specificity was 73%. The odds ratio for this cutoff
level was 5.4 (CI 2.4–12.3). For comparison, day 1 urine
output predicted DGF with an AUC of 0.931 (CI 0.894–0.967;
Po0.0001). At the optimal cutoff level of 1035 ml, the
sensitivity was 91% and the specificity was 80%.
The correlations between uNGAL and kidney function
(plasma creatinine, eGFR) at 3 weeks, 3 months, and 1 year
after transplantation were studied (Table 5). uNGAL
correlated with kidney graft function up to 3 months. The
mean length of stay in the hospital after kidney transplanta-
tion was 21 days (ranging from 15 to 43 days). Day 1 uNGAL
did not correlate with length of stay in the hospital
(R¼ 0.047, P¼NS).
We wanted to study whether uNGAL predicts DGF in
cases in which EGF was expected on the basis of early urine
output and decreasing plasma creatinine. First, we focused on
the 112 transplantations with day 1 urine output 41 l.
Despite good diuresis, 15 of these transplantations developed
DGF. Their mean day 1 uNGAL concentration was
significantly higher, 1217 ng/ml (s.d. 1228.9), compared with
460 ng/ml (s.d. 481.3, Po0.0001) of the 97 transplantations
with EGF. Day 1 uNGAL predicted DGF in this subgroup
Table 1 | Recipient pretransplantation characteristics
EGF DGFa P-value
N 106/176 (60.2%) 70/176 (39.8%)
Mean age, years (s.d.) 50.5 (12.8) 54.1 (13.3) NS
Gender
Female 45 (42.5%) 21 (29.6%) NS
Male 61 (57.5%) 49 (69.4%)
TX number
First TX 99 (93.4%) 62 (88.6%) NS
Re-TX 7 (6.6%) 8 (11.4%)
Underlying kidney disease
Polycystic disease 26 (24.5%) 16 (22.9%) NS
Glomerulonephritis 21 (19.8%) 14 (20.0%)
Diabetes mellitus 29 (27.4%) 19 (27.1%)
Other 30 (28.3%) 21 (30.0%)
Mode of dialysis
Hemodialysis 62 (58.5%) 52 (74.3%) 0.032
Peritoneal dialysis 44 (41.5%) 18 (25.7%)
Mean time on
dialysis, days (s.d.)
770 (571.1) 975 (598.9) 0.007
Abbreviations: DGF, delayed graft function; EGF, early graft function; NS, not
significant; s.d., standard deviation; TX, transplantation.
aDGF defined according to the Halloran criteria.23
Table 2 | Recipient posttransplantation characteristics
EGF (n=106
(60.2%))
DGF (n=70
(39.8%))a P-value
Initial CNI
Tacrolimus 24 (22.6%) 17 (24.3%) NS
Cyclosporine A 82 (77.4%) 53 (75.7%) NS
Induction therapy with
IL-2 receptor antagonist
15 (14.2%) 13 (18.6%) NS
Mean change in plasma
creatinine from pre-TX to
day 1 (mmol/l (s.d.))
117 (145.5) +17 (129.1) o0.0001
Mean plasma creatinine (mmol/l (s.d.))
Day 1 445 (198.8) 664 (191.8) o0.0001
Day 3 250 (148.3) 644 (191.9) o0.0001
Day 7 141 (57.2) 458 (193.9) o0.0001
3 Weeks 120 (38.6) 206 (112.5) o0.0001
3 Months 110 (27.4) 148 (48.8) o0.0001
1 Year 109 (38.8) 128 (41.9) 0.002
Mean eGFR, ml/min (s.d.)
3 Weeks 64.2 (19.9) 46.4 (21.2) o0.001
3 Months 69.7 (23.2) 58.9 (21.1) 0.003
1 Year 74.8 (24.4) 67.7 (23.5) 0.050
Mean urine output (ml per 24 h (s.d.))
Day 1 2544 (1526.5) 2406 (809.2) o0.0001
Day 3 574 (613.8) 713 (713.7) o0.0001
Day 7 2412 (779.8) 1274 (1007.5) o0.0001
Day 14 2661 (690.6) 1888 (1060.3) o0.0001
Number of rejections 4 (3.8%) 6 (8.6%) NS
Mean time to rejection
(days (s.d.))
8.7 (2.1) 20.8 (13.8) NS
1-Year patient survival 99.4% 98.6% NS
1-Year graft survival 99.1% 90.0% 0.005
Abbreviations: CNI, calcineurin inhibitor; DGF, delayed graft function; EGF, early graft
function; eGFR, estimated glomerular filtration rate (Cockcroft–Gault); IL-2 receptor
antagonist, interleukin-2 receptor antagonist (either basiliximab (n=19) or daclizu-
mab (n=9)); NS, not significant; TX, transplantation; s.d., standard deviation.
aDGF defined according to the Halloran criteria.23
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with an AUC of 0.696 (CI 0.526–0.866; P¼ 0.034). At the
560 ng/ml cutoff level, the sensitivity was 55% and specificity
was 74%. For comparison, day 1 urine output predicted DGF
with an AUC of 0.803 (CI 0.705–0.902; Po0.0001). At the
optimal cutoff level of 1690 ml, the sensitivity was 81% and
the specificity was 67%.
Secondly, we analyzed the cases in which plasma creatinine
had decreased from pretransplantation level, taken at arrival
to the transplantation center, to day 1 (n¼ 112). The mean
decrease in plasma creatinine in these patients was 149 mmol/l
(s.d. 125.2). In 86 cases, the decrease in plasma creatinine was
450 mmol/l, and 19 of these developed DGF. Their mean day
1 uNGAL concentration was significantly higher (1318 ng/ml,
s.d. 1245.9) compared with that of the 67 recipients with EGF
(398 ng/ml, s.d. 340.0; Po0.0001). A ROC analysis resulted
in an AUC of 0.744 (CI 0.570–0.918; P¼ 0.014). At the
560 ng/ml cutoff level, the sensitivity was 60% and specificity
was 75%. For comparison, the change in plasma creatinine
from pretransplantation level to day 1 could not predict DGF
(AUC 0.585; P¼NS).
Prolonged duration of DGF
To assess uNGAL’s potential in predicting prolonged DGF, we
divided the 70 DGF transplantations according to the
duration of DGF: p7 days, 8–13 days, and X14 days
(Table 6, and Figure 2).
A ROC analysis for day 1 uNGAL predicted DGF lasting
longer than 7 days, with an AUC of 0.748 (Po0.0001)
(Figure 3). At the cutoff level of 560 ng/ml, the sensitivity was
70% and the specificity was 70%. Day 1 uNGAL predicted
DGF lasting longer than 14 days, with an AUC of 0.748
(P¼ 0.005). At the cutoff level of 560 ng/ml, the sensitivity
was 83% and the specificity was 66%. We also analyzed the
predictive power of day 3 uNGAL in prolonged DGF. A ROC
analysis for day 3 uNGAL in predicting DGF lasting longer
than 7 days produced and AUC of 0.457 (CI 0.267–0.647;
P¼NS). A ROC analyses for day 3 uNGAL in predicting
DGF lasting longer than 14 days produced an AUC of 0.608
(CI 0.422–0.793; P¼NS).
Conventional DGF definition and slow graft function
The DGF group had significantly higher uNGAL concentra-
tions, compared with both slow (SGF) and immediate graft
function (IGF) groups defined according to Humar et al.5
(Table 7, Figure 4). Early after transplantation, the NGAL
Table 4 |Multivariate analysis of DGFa risk factors
P-value
Donor age (years) 0.315
Donor plasma creatinine (mmol/l) 0.891
Donor eGFR (ml/min) 0.600
Expanded criteria donors 0.484
Cold ischemia time (hours) 0.980
Recipient age (years) 0.958
Mode of dialysis (hemodialysis or peritoneal dialysis) 0.004
Time on dialysis before TX (days) 0.457
Change in plasma creatinine from pre-TX to day 1 0.891
Recipient day 1 urine output (ml) o0.0001
Recipient day 1 uNGAL (ng/ml) 0.019
Abbreviations: DGF, delayed graft function; eGFR, estimated glomerular filtration
rate (Cockcroft–Gault); TX, transplantation; uNGAL, urine neutrophil gelatinase-
associated lipocalin.
aDGF defined according to the Halloran criteria.23
Expanded criteria donors were defined using the Port criteria.22
Table 3 | Donor characteristics
EGF DGFa P-value
Mean age (years) 49.1 (9–75) 55.8 (9–75) 0.002
Gender
Female 44 (41.5%) 28 (40.0%) NS
Male 62 (58.5%) 42 (60.0%)
Cause of death
Cerebrovascular accident 75 (70.8%) 57 (81.4%) NS
Traumatic brain injury 33 (31.2%) 13 (18.6%)
Mean plasma creatinine
(mmol/l (s.d.))
63 (21.0) 64 (17.4) NS
Mean eGFR (ml/min (s.d.))b 124 (39.2) 115 (35.0) NS
History of hypertension 26 (24.5%) 24 (34.3%) NS
Expanded criteria donors 33 (31.1%) 36 (51.4%) 0.007
Need for cardiopulmonary
resuscitation
25 (23.6%) 10 (14.3%) NS
Antemortem intracranial surgery 19 (17.9%) 22 (31.4%) NS
Use of inotropes 63 (59.4%) 62 (88.6%) NS
Use of antidiuretic hormone 50 (47.2%) 38 (54.3%) NS
Multiorgan donor 39 (36.8%) 38 (54.3%) NS
Mean hospital days before
brain death (s.d.)
2.0 (2.5) 1.6 (1.3) NS
Mean cold ischemia time
(hours (s.d.))
21.3 (3.7) 22.9 (3.6) 0.007
Abbreviations: DGF, delayed graft function; EGF, early graft function; eGFR,
estimated glomerular filtration rate; NS, not significant; s.d., standard deviation.
aDGF defined according to the Halloran criteria.23
beGFR estimated by the Cockcroft–Gault equation35 in 96 adult donors and by the
Schwartz equation36 in three pediatric donors.
Expanded criteria donors were defined using the Port criteria.22
P = 0.005NS P<0.0001 P<0.0001 P<0.0001
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Figure 1 | The mean uNGAL concentrations between EGF and
DGF groups. The mean uNGAL concentrations in DGF and EGF
groups at all measured time points; before transplantation (day 0)
and after transplantation (days 1, 3, 7, and 14). The results are
expressed as means (þ s.e.m.). DGF¼delayed graft function,
defined according to the Halloran criteria23; EGF, early graft
function; NS, not significant; uNGAL, urine neutrophil gelatinase-
associated lipocalin.
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levels in the SGF group were similar to the levels in the DGF
group, and at later time points, they were similar to the IGF
group. At 1 year after transplantation, the mean plasma
creatinine was higher and eGFR was lower in the DGF group,
compared with IGF and SGF groups.
A ROC analysis for day 1 uNGAL in predicting
conventionally defined DGF produced an AUC of 0.736 (CI
0.642–0.830; Po0.0001). At the optimal 560 ng/ml cutoff
level, the sensitivity was 65%, and the specificity was 74%.
Day-1 uNGAL predicted SGF with an AUC of 0.648 (CI
0.474–0.822; P¼NS).
There were no significant differences in mean uNGAL
concentrations or renal transplant function between the DGF
transplantations defined by the Halloran criteria,23 and the DGF
transplantations defined by the conventional definition (Table 8).
NGAL in EGF transplantations
All EGF transplantations were divided into high and low
groups according to the measured uNGAL concentration on
Table 5 | The correlation between uNGAL and renal graft function at 3 months and 1 year after transplantation
3 Weeks 3 Months 1 Year
Creatinine eGFR Creatinine eGFR Creatinine eGFR
Day 1 uNGAL R=0.382 R=0.283 R=0.189 R=0.059 R=0.010 R=0.010
Po0.0001 Po0.0001 P=0.032 P=NS P=NS P=NS
Day 3 uNGAL R=0.553 R=0.571 R=0.359 R=0.337 R=0.267 R=0.125
Po0.0001 Po0.0001 Po0.0001 Po0.0001 P=0.002 P=NS
Day 7 uNGAL R=0.499 R=0.519 R=0.242 R=0.253 R=0.152 R=0.174
Po0.0001 Po0.0001 P=0.003 P=0.002 P=NS P=0.035
Day 14 uNGAL R=0.531 R=0.467 R=0.122 R=0.144 R=0.036 R=0.038
Po0.0001 Po0.0001 P=NS P=NS P=NS P=NS
Abbreviations: eGFR, estimated glomerular filtration rate (Cockcroft–Gault); NS, not significant; R, correlation coefficient; uNGAL, urine neutrophil gelatinase-associated
lipocalin.
Table 6 | Transplantation characteristics by the length of DGF
DGF p7 days
(n=17)a
DGF 8–14 days
(n=27)a
DGF X14 days
(n=26)a
P-value between
all groups
Mean donor age (years (s.d.)) 55.2 (8.7) 56.0 (13.9) 56.0 (10.7) NS
Mean cold ischemia time (hours (s.d.)) 23.4 (3.3) 22.0 (3.9) 23.3 (3.4) NS
Recipient age (years (s.d.)) 54.0 (9.3) 56.2 (13.4) 52.0 (15.4) NS
Mode of dialysis before TX
Hemodialysis 15 21 19 NS
Peritoneal dialysis 2 6 7 NS
Mean time on dialysis before TX (days (s.d.)) 1082 (675.4) 939 (694.0) 929 (430.9) NS
Mean day 1 urine output (ml (s.d.)) 755 (687.4) 519 (651.7) 439 (497.6) NS
Mean uNGAL (ng/ml (s.d.))
Pre-TX 1733 (1972.6) 1597 (1172.6) 1150 (536.8) NS
Day 1 1153 (1202.1) 1044 (856.2) 963 (530.0) NS
Day 3 774 (837.7) 982 (1211.8) 1200 (1548.1) NS
Day 7 133 (181.5) 642 (860.2) 984 (1308.2) 0.001
Day 14 39 (29.9) 84 (89.8) 706 (1190.3) 0.004
Mean plasma creatinine at 1-year post-TX (mmol/l (s.d.)) 115 (35.1) 117 (31.9) 156 (47.3) 0.002
Mean eGFR at 1-year post-TX (ml/min (s.d.)) 75.5 (25.1) 70.7 (22.1) 56.4 (20.1) 0.031
1-Year graft survival 100% 100% 73.1% 0.001
Abbreviations: DGF, delayed graft function; eGFR, estimated glomerular filtration rate (Cockcroft–Gault); s.d., standard deviation; TX, transplantation; uNGAL, urine neutrophil
gelatinase-associated lipocalin.
aDGF defined according to the Halloran criteria.23
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Figure 2 | The uNGAL concentrations according to the length
of DGF. The mean uNGAL concentrations before (day 0) and after
transplantation (days 1, 3, 7, and 14) in DGF groups with onset
of function in o8 days, between 8 and 14 days, and at 14 days
or later. The results are expressed as means (þ s.e.m.). DGF, delayed
graft function, defined according to the Halloran criteria23; NS,
not significant; uNGAL, urine neutrophil gelatinase-associated lipocalin.
92 Kidney International (2011) 79, 89–98
or ig ina l a r t i c l e ME Hollmen et al.: Urine NGAL and DGF
days 1, 3, 7, and 14, using the means 468, 120, 86, and
47 ng/ml, respectively, as cutoff points (Table 9).
High days 3 and 7 uNGAL concentrations were associated
with higher plasma creatinine and lower eGFR at 3 weeks
posttransplantation, but not at 3 months or 1 year after
transplantation.
DISCUSSION
DGF is a common complication after kidney transplantation,
and it seems to become more frequent with the relaxation of
donor criteria,24,25 as demonstrated in this report with a DGF
rate of almost 40%. In the literature, the DGF rates vary in
deceased donor transplantations from below 10 to 50%.10,26
In the clinic, the diagnosis of DGF is usually made within a
few days after transplantation based on diuresis, plasma
creatinine, and need for dialysis. DGF is, so far, not causally
treatable. Provided that the diagnosis of DGF could be made
immediately after transplantation, the transplant clinicians
could earlier individualize patient care, for example, by
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Figure 3 |The ROC curves for day 1 uNGAL in predicting DGF lasting longer than 7 days and for DGF lasting longer than 14 days.
The ROC analyses for day 1 uNGAL in predicting DGF lasting longer than 7 days and in predicting DGF lasting longer than 14 days. AUC,
area under the curve; CI, confidence interval; DGF, delayed graft function, defined according to the Halloran criteria23; ROC, receiver
operating characteristic; uNGAL, urine neutrophil gelatinase-associated lipocalin.
Table 7 | Posttransplantation differences among IGF, SGF,
and DGF groups
IGF (n=94) SGF (n=16) DGF (n=66)
P-value
between
all groups
Mean uNGAL (ng/ml (s.d.))
Pre-TX 1002 (991.9) 1858 (1775.9) 1429 (969.8) NS
Day 1 462 (475.6) 946 (1070.8) 931 (715.1) o0.0001
Day 3 82 (126.4)a 288 (163.1)a,b1032 (1230.7)b o0.0001
Day 7 55 (68.4)c 141 (189.4)c,d 665 (1006.1)d o0.0001
Day 14 34 (110.5) 34 (27.8)e 274 (729.5)e 0.011
Mean plasma creatinine (mmol/l (s.d.))
Day 1 425 (177.6)a 710 (270.0)a 640 (204.2) o0.0001
Day 3 215 (94.9)a 653 (185.3)a 620 (211.7) o0.0001
Day 7 135 (59.6)a 304 (136.9)a,d 450 (205.4)d o0.0001
3 Week 116 (38.0)b 152 (46.0)b 209 (112.5) o0.0001
3 Month 107 (25.3)b 128 (32.5)b 149 (70.6) o0.0001
1 Year 107 (36.8) 118 (41.5) 130 (42.7) 0.002
Mean eGFR (ml/min (s.d.))
3 Week 66.1 (19.8) 55.7 (19.0) 44.5 (19.7) o0.0001
3 Month 71 (23.7) 66 (21.3) 57 (20.2) 0.001
1 Year 75.7 (24.5) 75.9 (26.6) 65.5 (21.5) 0.03
1-Year patient
survival
98.9% 100% 98.5% NS
1-Year graft survival 98.9% 100% 89.4% 0.012
Abbreviations: DGF, delayed graft function, defined as need for dialysis during the
first week after transplantation; eGFR, estimated glomerular filtration rate
(Cockcroft–Gault); IGF, immediate graft function; NS, not significant; s.d., standard
deviation; SGF, slow graft function; uNGAL, urine neutrophil gelatinase-associated
lipocalin.
aPo0.0001 between the IGF and SGF groups.
bPp0.005 between the DGF and SGF groups.
cP=0.01 between the IGF and SGF groups.
dP=0.009 between the DGF and SGF groups.
eP=0.031 between the DGF and SGF groups.
Groups defined according to Humar et al.5
P=0.01NS P=0.0002 P<0.00001 P<0.00001
u
N
G
AL
 (n
g/m
l)
2500
2000
1500
1000
500
0
IF  SGF  DGF IF  SGF  DGF IF  SGF DGF IF  SGF  DGF IF  SGF  DGF
N = 44 N = 8 N = 18 N = 87 N = 12 N = 35 N = 84 N = 14 N = 40 N = 87 N = 14N = 50 N = 83 N = 16 N = 56
Day 0 Day 1 Day 3 Day 7 Day 14
Figure 4 |The mean uNGAL concentrations in DGF, SGF, and
IGF groups. The mean uNGAL concentrations in DGF, SGF, and
IGF groups before transplantation (day 0) and after
transplantation at all measured time points (days 1, 3, 7, and 14).
Groups were defined according to Humar et al.5 The results are
expressed as means (þ s.e.m.). DGF, delayed graft function,
defined as required for dialysis during the first week after
transplantation, uNGAL, urine neutrophil gelatinase-associated
lipocalin; IGF, immediate graft function; SGF, slow graft function.
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adjusting the initiation and dose of calcineurin inhibitors,
avoiding other nephrotoxic agents, and scheduling for
posttransplantation dialysis. In addition, this would enable
the development of new DGF treatment strategies in the
future.
In kidney transplantation, the inevitable cold ischemia
and warm reperfusion affect the distal nephron and result in
similar morphological and functional findings, as found in
human acute kidney injury in general.27 In rodents, the main
site for NGAL production is the distal nephron.28 Kidney
transplantation can be regarded as a model for human acute
kidney injury in which NGAL production occurs.27 NGAL
has also been suggested as an early marker for DGF,17–21 but
the data on that are still scarce. The similarities, differences,
and limitations regarding previous reports on NGAL and
clinical kidney transplantation17–21 are listed in Table 10. In
this study, we wanted to test the findings of the few previous
studies in a larger kidney transplant patient population, with
a special emphasis on prolonged DGF. Prolonged DGF has
been found to be more detrimental to the transplanted
kidney, compared with DGF of a few days’ duration,4,9 as also
demonstrated in this study. We were also interested to see
whether uNGAL has any importance in renal transplants
with EGF.
We chose urine as sample material, as uNGAL has been
suggested to represent the damage in the kidney,29 and it has
previously been shown to result from local synthesis in the
kidney rather than filtration from blood.30
The uNGAL levels have previously been shown to be
elevated in patients with chronic kidney disease.31,32 In this
study, the pretransplantation uNGAL is representative of
levels in dialysis-dependent patients with end-stage renal
disease. The high uNGAL levels in these patients might just
result from decreased GFR, but also might reflect ongoing
damage in the kidney.33 We used the pretransplantation
concentrations as a reference for posttransplantation uNGAL
measurements. uNGAL levels were similar in EGF and DGF
groups, and were not used in predicting onset of function
after transplantation.
In this study, the donors were older, expanded criteria
donors were more common, mean cold ischemia time was
longer, pretransplantation hemodialysis was more common,
Table 8 | The differences between DGF groups defined by the
Halloran criteria23 and the conventional criteria (need for
posttransplantation dialysis during the first week after
transplantation)
DGF Halloran
(n=70)
DGF
conventional
(n=66) P-value
Mean day 1 urine output
(ml (s.d.))
574 (611.8) 497 (536.0) NS
Mean uNGAL (ng/ml (s.d.))
Pre-TX 1533 (1360.6) 1429 (969.8) NS
Day 1 1045 (851.7) 931 (715.1) NS
Day 3 979 (1201.5) 1032 (1230.7) NS
Day 7 591 (924.8) 665 (1006.1) NS
Day 14 259 (706.8) 274 (729.5) NS
Mean plasma creatinine (mmol/l (s.d.))
Day 1 662 (209.9) 640 (204.2) NS
Day 3 644 (205.3) 620 (211.7) NS
Day 7 458 (198.9) 450 (205.4) NS
3 Week 206 (111.5) 209 (112.5) NS
3 Month 147 (69.1) 149 (70.6) NS
1 Year 128 (41.5) 130 (42.7) NS
Mean eGFR at 1-year
post-TX (ml/min (s.d.))
67.7 (23.4) 65.5 (21.5) NS
1-Year graft survival 90.0% 89.4% NS
Abbreviations: DGF, delayed graft function; eGFR, estimated glomerular filtration
rate (Cockcroft–Gault); NS, not significant; s.d., standard deviation; uNGAL, urine
neutrophil gelatinase-associated lipocalin.
Table 9 | High (above the mean) and low (below the mean) uNGAL concentration and kidney transplant function at 3 weeks,
3 months, and 1 year after transplantation in the transplantations with EGF
3 Weeks 3 Months 1 Year
eGFR Creatinine eGFR Creatinine eGFR Creatinine
Day 1 uNGAL
High (X468 ng/ml) 65 (19.1) NS 126 (44.8) NS 71 (25.0) NS 112 (28.4) NS 80 (27.9) NS 107 (28.9) NS
Low (o468 ng/ml) 66 (19.9) 114 (29.8) 70 (21.9) 105 (24.8) 75 (22.5) 109 (43.7)
Day 3 uNGAL
High (X120 ng/ml) 52 (13.9) 0.001 150 (40.3) o0.0001 68 (25.0) NS 116 (21.5) 0.027 74 (27.1) NS 118 (48.0) NS
Low (o120 ng/ml) 68 (20.3) 110 (31.4) 72 (23.1) 104 (27.1) 77 (23.4) 105 (36.0)
Day 7 uNGAL
High (X86 ng/ml) 51 (12.2) o0.0001 146 (43.9) 0.001 67 (26.0) NS 113 (19.8) NS 74 (30.9) NS 115 (49.3) NS
Low (o86 ng/ml) 68 (19.5) 114 (35.4) 72 (22.8) 108 (28.3) 75 (23.4) 109 (39.9)
Day 14 uNGAL
High (X47 ng/ml) 56 (19.0) 0.015 127 (32.4) NS 67 (18.2) NS 102 (16.0) NS 76 (18.8) NS 94 (26.7) NS
Low (o47 ng/ml) 66 (19.4) 118 (37.4) 69 (24.8) 110 (29.6) 73 (24.9) 113 (41.1)
Abbreviations: EGF, early graft function; eGFR, estimated glomerular filtration rate (Cockcroft–Gault); NS, not significant; uNGAL, urine neutrophil gelatinase-associated
lipocalin.
The data are expressed as means with standard deviation.
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and time on dialysis before transplantation was longer in the
DGF group, compared with the EGF group. All these are
regarded as significant risk factors for DGF.34 However, in
our multivariate analysis, only day 1 uNGAL, day 1 urine
output, and mode of dialysis emerged as independent
predictors for DGF. As our ROC analysis showed, day 1
uNGAL predicted DGF, but moderately compared with day 1
urine output in this study. The AUC was also inferior
compared with those reported previously.18,19 Parikh et al.18
reported an excellent AUC for uNGAL in prediction for DGF,
but the patient population was smaller and more hetero-
geneous compared with our study. Hall et al.19 reported a
slightly better AUC for uNGAL in prediction of DGF
compared with ours, but inferior compared with the Parikh
et al. study. The patient population in the Hall study is
similar to our study, apart from being a multicenter study.
The different NGAL analysis methods and sample materials
maybe other reasons why our results are not as optimistic as
those reported previously (Table 10).
In clinical practice, the early diagnosis of DGF is most
difficult in cases in which diuresis or decreasing plasma
creatinine seem to suggest EGF, but the patient, nevertheless,
develops DGF. In these cases, day 1 uNGAL gave additional
value in the prediction of DGF at a time when a clinical
diagnosis of DGF was yet impossible. Of great importance is
our finding that day 1 uNGAL predicted prolonged
DGF, which is a clinically significant complication, leading
to significantly worse 1-year graft survival compared with
short DGF.
We used Halloran’s DGF definition,23 as it takes into
account all clinically relevant indicators of poor allograft
function. This definition includes patients with good
diuresis, but without decreasing plasma creatinine, and
excludes patients needing only one dialysis session after
transplantation because of, for example, high potassium or
fluid overload. However, the most commonly used definition
for DGF is need for dialysis during the first week after
transplantation. Lack of uniform DGF definition complicates
comparison of research data. Thus, we found it important to
test the predictive value of uNGAL also with the commonly
used DGF definition, and found no significant differences in
our results when either of these definitions was used.
All the transplanted grafts, and also the EGF grafts, are
susceptible to ischemia-reperfusion injury and the damage
caused by it. Therefore, we examined whether uNGAL could
predict the level of graft function in EGF transplantations.
High uNGAL levels were associated with worse kidney
function at 3 weeks posttransplantation, but not at 3 months,
or at 1 year after transplantation. This may suggest that high
uNGAL in the EGF transplantations reflects a more
pronounced short-term injury, which seems to be repairable
and is not seen in the long run. Furthermore, the uNGAL
concentrations in the EGF transplantations decreased within
3 days nearly to the levels seen in healthy individuals. This
also enables the use of uNGAL as a marker for new-onset
kidney injury in kidney recipient follow-up.
There are certain limitations to this study. It was a single-
center study. As we examined only one biomarker, we could
Table 10 | Comparison between previous studies on NGAL and prediction of DGF and our study
First author Similarities Differences Limitations
Mishra et al.17 Single center
Prospective
Single biomarker
Sample material (biopsies)
Method (IHC)
Patient population
Solely pediatric patients
Number of patients limited (n=25)
Living and deceased donor TXs
No analyses of other factors associated with
DGF (age, CIT, and so on)
No multivariate analysis
Parikh et al.18 Sample material (urine)
Single center
Prospective
Method (ELISA)
Sample collection and timing
Patient population
Multibiomarker
Both adult and pediatric patients
Living and deceased donor TXs
No standardized sampling
No data on anuric patients/patients without sample
Number of patients limited (n=53)
No data on pretransplantation NGAL
Kusaka et al.20 Single center
Prospective
Single biomarker
Sample material (serum)
Method (ELISA)
Patient population
Living and non-heart beating donor TXs
Number of patients limited (n=16)
No analyses of other factors associated with DGF
(age, CIT, and so on)
No multivariate analysis
Lebkowska et al.21 Sample collection
time points
Single center
Prospective
Single biomarker
Sample material (serum)
Method (ELISA)
Solely hemodialysis patients
Number of patients limited (n=41)
DGF not defined
No analyses of other factors associated with DGF
(age, CIT, and so on)
No multivariate analysis
Hall et al.19 Patient population
Solely deceased donor TXs
Sample material (urine)
Prospective
Multicentre
Method (ELISA)
Standardized sampling during
the first postoperative day
Multibiomarker
No data on anuric patients/patients without sample
No long-term follow-up
No data on pretransplantation NGAL
Abbreviations: CIT, cold ischemia time; DGF, delayed graft function; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry; TX, transplantation.
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not evaluate our NGAL results in relation to other potential
DGF biomarkers. We learnt from this study that the urine
samples taken on the first day after transplantation are the
most important; thus, the sample collection should have been
better standardized during the early hours after transplanta-
tion. Confounding effects of medication, surgery, dialysis,
and urine composition on NGAL analyzes, are not known
and could not be eliminated.
Our study also has several strengths. It was a nationwide
study, with a background population of 5 million people, and
it is so far the largest study on NGAL and DGF. We analyzed
our data using two different DGF definitions. We analyzed
pretransplantation uNGAL levels to evaluate uNGAL con-
centration in dialysis-dependent patients with end-stage
kidney disease. After transplantation, uNGAL was measured
at several time points, and we are the first to report uNGAL
levels in kidney transplant patients during the first 2 weeks
after transplantation and the association of uNGAL and
1-year graft function. We also studied uNGAL levels in cases
in which EGF was expected on the basis of diuresis and
creatinine decrease, as DGF diagnosis is the most difficult in
this patient group.
On the basis of these results, we suggest the following
clinical implications (1) uNGAL allows prediction of DGF,
even in patients with good urine output and decreasing
creatinine; (2) low uNGAL levels in oliguric patients after
kidney transplantation suggest that oliguria might also be
caused by other reasons, such as suboptimal fluid balance; (3)
uNGAL predicts prolonged DGF and thus identifies patients
with severe kidney injury and inferior long-term outcome;
(4). uNGAL provides a simple test to quantify the recovery
from kidney injury. If uNGAL reaches normal values, a
subsequent rise in uNGAL concentration would be suggestive
of a new kidney injury. In the future, studies are needed to
evaluate the association of NGAL and kidney histology
during DGF, and the role of NGAL in other situations of
kidney transplant dysfunction such as rejection, calcineurin
toxicity, and de novo glomerulonephritis. In the most optimal
scenario, NGAL measured in the donor before organ
retrieval, could predict DGF.
In conclusion, day 1 uNGAL predicted DGF with
moderate sensitivity and specificity in cases in which EGF
was, according to early clinical findings, expected but
ultimately did not occur. uNGAL predicted prolonged DGF
on the first day after transplantation. The definition of DGF
did not affect our results. In the EGF transplantations, high
uNGAL was associated with worse level of kidney function
during the early weeks after transplantation, but did not have
long-term effects.
PATIENTS AND METHODS
The study population consisted of 176 adult, dialysis-
dependent, kidney transplant recipients, recruited between
August 2007 and December 2008, and their 99 consecutive,
deceased donors in the Helsinki University Hospital, the only
transplantation center in Finland. The minimum follow-up
was 1 year. A written informed consent was obtained from
the recipients before enrollment. The study protocol was
approved by the local ethics committee.
The clinical data were obtained from the patients’ records
and the Finnish Kidney Transplant Registry database. Donor
variables collected were age, gender, history of hypertension,
plasma creatinine, eGFR estimated by the Cockcroft–Gault
equation35 in adults, and by the Schwartz equation36 in three
pediatric donors, need for antemortem intracranial surgery,
need for cardiopulmonary resuscitation, use of inotropes and
antidiuretic hormone, length of hospital stay before brain
death, cause of death, expanded criteria donors, multiorgan
or kidney-only donation, and cold ischemia time. Expanded
criteria donors were defined as donors over 60, or over
50 years of age, with at least two of the following criteria:
hypertension, plasma creatinine 4132 mmol/l, and cerebro-
vascular accident as cause of death.22 None of the donors had
diabetes, and all were Caucasian. All donors received
intravenous steroids before the organ retrieval operation
and Mannitol before in situ perfusion. University of
Wisconsin solution was used for in situ perfusion and cold
storage preservation of the kidneys.
Recipient variables collected were age; gender; underlying
kidney disease; number of previous transplants; mode of and
time on dialysis before transplantation; urine output daily
after transplantation during the stay in the Transplant unit;
plasma creatinine on arrival for transplantation, daily after
transplantation during the stay in the transplant unit, and at
1 year; and eGFR at 3 weeks, 3 months, and 1 year after
transplantation. Calcineurin inhibitor (cyclosporine
(n¼ 135) or tacrolimus (n¼ 41)) was administered orally
to all recipients before transplantation, and continued after
transplantation, with target levels of 200–250 mg/ml for
cyclosporine and 6–12 mg/ml for tacrolimus. Other immuno-
suppression consisted of mycophenolate mofetil (target dose:
1 g twice a day for patients with cyclosporine, and 500 mg
twice a day for patients with tacrolimus) and steroids.
Induction immunosuppression with interleukin-2 receptor
antagonist was given to 28 recipients (basiliximab (n¼ 19)
and daclizumab (n¼ 9)).
The primary outcome variable was DGF. DGF was
defined, as described by Halloran et al.,23 as oliguria o1 l
every 24 h for 42 days, or plasma creatinine concentration
4500 mmol/l throughout the first week, or 41 dialysis
session needed during the first week. The results were also
calculated using the conventional DGF definition: need for
dialysis during the first week after transplantation. Here, the
early functioning grafts were additionally divided into two
groups, according to Humar et al.,5 to SGF, in which plasma
creatinine remained 4265 mmol/l for 45 days after trans-
plantation without need for dialysis, and to IGF.
NGAL sample collection and detection
Urine samples for NGAL assays were taken on arrival to the
transplant unit (pretransplant sample), and after trans-
plantation in the morning of days 1, 3, 7, and 14. The
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pretransplantation sample was taken to evaluate uNGAL
concentration in dialysis-dependent patients with end-stage
kidney disease, and used as a reference level for uNGAL
measurements after transplantation. Before transplantation,
49 patients were anuric and 57 patients were oliguric (urine
output o500 ml every 24 h). The pretransplantation urine
sample was obtained from 70 recipients. Day-1 urine samples
were taken in the first morning after the transplant surgery in
the ward, at a mean of 12.2 h (range 2.1–31.3) after
reperfusion of the graft, from the urine catheter. The urine
samples at later time points were collected from the urine
catheter or using the clean-catch method. The day 1 urine
sample was obtained from 134 patients, the day 3 urine
sample from 139 patients, the day 7 urine sample from 151
patients, and the day 14 sample from 156 patients. After
collection, the urine samples were immediately centrifuged,
and the supernatant was stored at 70 1C without delay.
The uNGAL assay was performed by a two-step chemi-
luminescent microparticle immunoassay on a standardized
clinical platform (ARCHITECT, Abbott Diagnostics, Abbott
Park, IL, USA), as previously described.37
Statistical analyses
SPSS software, version 16.0 (SPSS, Chicago, IL, USA) was
used for statistical analyses. Data are expressed as means with
standard deviations (s.d.) or as absolute numbers with
percentages. All analyzed variables were tested for distribu-
tion. The t-test and analysis of variance were used for samples
with normal distribution, and Mann–Whitney U- and
Kruskal–Wallis tests were used for samples with skewed
distribution. w2- and Fisher’s exact tests were used in the
analyses of contingency tables. The correlations were
analyzed using the Pearson’s correlation coefficient for
normally distributed parameters and the Spearman correla-
tion coefficient for parameters with skewed distribution. To
assess DGF predictors, a multilogistic regression analysis
(forward, conditional) was used. Factors significantly differ-
ing between the DGF and EGF groups in the univariate
analyses (donor age, number of expanded criteria donors,
cold ischemia time, mode of and time on dialysis before
transplantation, mean change in creatinine from pretrans-
plantation to day 1, day 1 urine output, and day 1 uNGAL),
and also the clinically relevant factors in this respect (donor
plasma creatinine, donor eGFR, and recipient age) were
included in the multivariate analysis. The factors in the
multivariate analysis consisted of categorical variables (mode
of dialysis, expanded criteria donors) and the covariates
consisted of continuous variables. ROC analyses were
performed to assess NGAL’s potential to predict DGF. The
optimal cutoff level was defined by the largest sum of
sensitivity and specificity. The odds ratio was calculated for
the optimal AUC. A P-value o0.05 was considered
significant.
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